Portfolio company
Genecker
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
Genecker develops CRISPR-based liquid biopsy platforms for early cancer detection and recurrence monitoring, serving healthcare providers and research institutions.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Infiniplex
This company develops liquid biopsy solutions using blood tests to monitor genetic biomarkers for cancer screening and precision oncology decisions for healthcare providers.
Epiliquid
This company develops blood-based liquid biopsy tests for early cancer detection and monitoring, serving clinical laboratories and medical practitioners.
Genomill Health
Genomill Health develops targeted sequencing technology for liquid biopsies to assist clinical laboratories and pharmaceutical companies with precision cancer diagnostics.
Avant Genomics
The company develops an automated platform for liquid biopsy sample preparation to assist clinical laboratories in cancer detection and monitoring.
Xgenera
Xgenera develops a multi-cancer early detection blood test to help clinicians and patients identify multiple cancer types at their earliest stages.
AnchorDx
This company develops non-invasive liquid biopsy tests and diagnostic tools for early cancer screening, diagnosis and recurrence monitoring for healthcare providers and patients.
Dxcover
This company develops an artificial intelligence platform and liquid biopsy blood tests for healthcare providers to achieve earlier cancer detection.
GeneCentric
This company develops gene expression-based liquid biopsy platforms and biomarkers to help pharmaceutical and diagnostic firms identify cancer treatment responders.
